Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
If you are wondering whether Biogen’s current share price gives you good value for the risk you are taking, you are not alone.
Over the last year the stock returned 25.0%. The 3 year and 5 year returns were declines of 36.6% and 32.1%, alongside a 7 day return of 4.8%, and a 30 day and year to date return of 1.2%.
Recent attention on Biogen has centered on its position in pharmaceuticals and biotech, with investors weighing how its product portfolio and pipeline might justify the current share price. This backdrop helps explain why the stock has seen both stronger recent returns over 1 year and weaker performance over longer time frames such as 3 and 5 years.
Biogen currently has a valuation score of 5/6, reflecting that it screens as undervalued on 5 of 6 checks. Next, we will walk through what different valuation methods say about that score and finish with a broader way to think about value beyond any single model.
Biogen delivered 25.0% returns over the last year. See how this stacks up to the rest of the Biotechs industry.
A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and then discounting those back to their value in today’s dollars.
For Biogen, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $2.18b, and analyst and extrapolated estimates suggest free cash flow in the range of roughly $2.7b to $3.0b per year over the next decade, with Simply Wall St extending the projections beyond the initial analyst horizon.
Discounting those projected cash flows gives an estimated intrinsic value of about $375.90 per share. Compared with the current share price, the DCF output implies the stock is 52.1% undervalued according to this model, which is a sizable gap for investors to consider.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Biogen is undervalued by 52.1%. Track this in your watchlist or portfolio, or discover 875 more undervalued stocks based on cash flows.
BIIB Discounted Cash Flow as at Feb 2026
Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Biogen.
For profitable companies like Biogen, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings. A higher or lower P/E can make sense depending on what investors expect for future growth and how much risk they see in those earnings.
Biogen currently trades on a P/E of 16.41x. That sits below both the Biotechs industry average P/E of 20.27x and the peer group average of 20.14x, so the market is assigning Biogen a lower earnings multiple than many comparable companies.
Simply Wall St also provides a proprietary “Fair Ratio” of 22.58x. This is an estimate of the P/E you might expect for Biogen given factors such as its earnings growth profile, industry, profit margins, market cap and risk characteristics. Because it is tailored to the company, this Fair Ratio can be more informative than a simple comparison with peers or the broad industry, which may differ on growth, risk and profitability.
Comparing the Fair Ratio of 22.58x with the current P/E of 16.41x suggests that Biogen’s shares are trading below that company specific reference point.
Result: UNDERVALUED
NasdaqGS:BIIB P/E Ratio as at Feb 2026
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1426 companies where insiders are betting big on explosive growth.
Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives.
A Narrative is simply your story about a company, written in numbers. You set your own view of fair value and your expectations for future revenue, earnings and margins instead of relying only on preset models.
On Simply Wall St, Narratives live in the Community page and help you connect three things in one place: Biogen’s story, a financial forecast and a resulting fair value that you can compare with the current share price to decide whether the stock looks expensive or cheap to you.
Because Narratives on the platform are refreshed when new information such as news or earnings is added, your view on Biogen can stay aligned with what is happening. You can also see how other investors using the tool, including those with the highest and lowest fair value estimates, interpret the same numbers in very different ways.
Do you think there’s more to the story for Biogen? Head over to our Community to see what others are saying!
NasdaqGS:BIIB 1-Year Stock Price Chart
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BIIB.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
More Stories
West Virginia House Finance Committee fast-tracks teacher, state police pay raise
UCLA CFO out days after alleging history of financial mismanagement
Fed’s Barr outlines AI risks to finance, labor market